CRISPR Therapeutics Appoints Chief Business Officer
This article was originally published in Scrip
Executive Summary
CRISPR Therapeutics, a biopharmaceutical company focused on translating CRISPR-Cas9 gene-editing technology into cures for serious human diseases, has appointed Dr. Samarth Kulkarni chief business officer and Dr. Michael Bruce senior vice-president of program portfolio and alliance management.